What is the first-line treatment for narcolepsy and its mechanism of action?

What is the first-line treatment for narcolepsy and its mechanism of action?

• A. Modafinil; orexin (hypocretin) agonist
• B. Methylphenidate; dopamine reuptake inhibitor
• C. Amphetamine; norepinephrine reuptake inhibitor
• D. Sodium oxybate; GABA-B agonist

Answer: (A)

Narcolepsy-related daytime sleepiness is best treated with wake-promoting therapy to restore alertness and functioning. Modafinil is the first-line option because it reliably improves daytime wakefulness with a lower risk of abuse and fewer cardiovascular or stimulant-related side effects than traditional stimulants. The mechanism is best described as promoting wakefulness via the orexin (hypocretin) system. Modafinil is thought to enhance orexin signaling in the hypothalamus, which stabilizes wakefulness; it may also involve other pathways (such as dopamine reuptake inhibition), but the key idea is boosting orexin-driven wake promotion. While the exact mechanism isn’t fully settled, this orexin-related action is the rationale behind its use as a first-line therapy. Methylphenidate and amphetamine are potent stimulants with higher abuse potential and more adverse effects, making them less ideal as first-line choices. Sodium oxybate helps with nighttime sleep and may reduce cataplexy but is not used primarily to treat daytime sleepiness, so it isn’t the preferred first-line option for wakefulness.

Narcolepsy-related daytime sleepiness is best treated with wake-promoting therapy to restore alertness and functioning. Modafinil is the first-line option because it reliably improves daytime wakefulness with a lower risk of abuse and fewer cardiovascular or stimulant-related side effects than traditional stimulants.

The mechanism is best described as promoting wakefulness via the orexin (hypocretin) system. Modafinil is thought to enhance orexin signaling in the hypothalamus, which stabilizes wakefulness; it may also involve other pathways (such as dopamine reuptake inhibition), but the key idea is boosting orexin-driven wake promotion. While the exact mechanism isn’t fully settled, this orexin-related action is the rationale behind its use as a first-line therapy.

Methylphenidate and amphetamine are potent stimulants with higher abuse potential and more adverse effects, making them less ideal as first-line choices. Sodium oxybate helps with nighttime sleep and may reduce cataplexy but is not used primarily to treat daytime sleepiness, so it isn’t the preferred first-line option for wakefulness.